PTC Therapeutics, Inc.

As of June 30, 2026, PTC Therapeutics, Inc. carries a market capitalization of 5.97B, placing it among publicly traded companies globally. Its enterprise value stands at 4.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PTC Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, PTC Therapeutics, Inc. has 83.33M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.58, and the price-to-book ratio stands at -41.22.

As of June 30, 2026, PTC Therapeutics, Inc. trades at an EV/EBITDA multiple of 29.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 42.07 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.62B versus a market cap of 5.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PTC Therapeutics, Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -421.18, indicating conservative leverage, while an interest coverage ratio of 0.98 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -1.30, reflecting losses generated across the asset base. The company generates approximately 902,824.52 in revenue per employee across its workforce of 978.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.13 indicates how many times PTC Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PTC Therapeutics, Inc. recorded an income tax benefit of -25.11M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -58.71M and -33.60M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, PTC Therapeutics, Inc.'s stock has declined approximately 2.64% over the past 52 weeks. The 50-day moving average sits at 58.16, while the 200-day moving average is 61.54.

Over the twelve months ended June 30, 2026, PTC Therapeutics, Inc. generated 882.96M in revenue and converted that into -33.60M in net income, yielding earnings per share of -0.39. EBITDA reached 158.34M, while operating income came in at 102.17M.

As of June 30, 2026, PTC Therapeutics, Inc. holds 1.95B in cash and equivalents against 609.62M in total debt, resulting in a net debt position of -401.69M. Total book value stands at -144.74M, with working capital of 1.62B providing operational flexibility.

PTC Therapeutics, Inc. produced -26.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -264.39M in capital expenditures, free cash flow totaled -291.09M - equivalent to -3.59 per share.

Over the twelve months ended June 30, 2026, PTC Therapeutics, Inc. posted a gross margin of 92.99, reflecting its pricing power and cost economics. The operating margin of 11.57 and net profit margin of -3.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.86, meaning PTC Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, PTC Therapeutics, Inc. has an Altman Z-Score of 1.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.